DK2906718T3 - Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf - Google Patents
Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf Download PDFInfo
- Publication number
- DK2906718T3 DK2906718T3 DK13821939.9T DK13821939T DK2906718T3 DK 2906718 T3 DK2906718 T3 DK 2906718T3 DK 13821939 T DK13821939 T DK 13821939T DK 2906718 T3 DK2906718 T3 DK 2906718T3
- Authority
- DK
- Denmark
- Prior art keywords
- progestion
- maf
- prostate
- diagnosis
- procedure
- Prior art date
Links
Classifications
-
- G01N33/57555—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713318P | 2012-10-12 | 2012-10-12 | |
| PCT/IB2013/002866 WO2014057357A2 (en) | 2012-10-12 | 2013-10-09 | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2906718T3 true DK2906718T3 (da) | 2019-07-01 |
Family
ID=49998595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13821939.9T DK2906718T3 (da) | 2012-10-12 | 2013-10-09 | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20140105918A1 (enExample) |
| EP (2) | EP2906718B1 (enExample) |
| JP (3) | JP6074049B2 (enExample) |
| KR (1) | KR101872965B1 (enExample) |
| CN (1) | CN104995313A (enExample) |
| AU (1) | AU2016213773B2 (enExample) |
| BR (1) | BR112015008255B1 (enExample) |
| CA (1) | CA2888122A1 (enExample) |
| DK (1) | DK2906718T3 (enExample) |
| ES (2) | ES2906586T3 (enExample) |
| HK (1) | HK1213946A1 (enExample) |
| MX (1) | MX365421B (enExample) |
| WO (1) | WO2014057357A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
| JP6074049B2 (ja) | 2012-10-12 | 2017-02-01 | インバイオモーション エセ.エレ. | c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US11206976B2 (en) * | 2014-10-16 | 2021-12-28 | New York University | Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system |
| BR112017012515A2 (en) | 2014-12-11 | 2018-01-02 | Inbiomotion S.L. | binding members for human c-maf |
| US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
| PL3458610T3 (pl) * | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| CZ2016821A3 (cs) * | 2016-12-22 | 2018-07-04 | České vysoké učení technické v Praze | Kombinace pro radionuklidovou terapii pro použití jako léčivo |
| BR112020010192A2 (pt) | 2017-11-22 | 2020-10-13 | Inbiomotion S.L. | tratamento terapêutico de câncer de mama com base no status de c-maf |
| TW202012637A (zh) * | 2018-04-24 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| WO2024130224A2 (en) * | 2022-12-16 | 2024-06-20 | Purdue Research Foundation | Stapled peptides for sensitization of cancer to treatment |
| CN116287250B (zh) * | 2023-01-18 | 2025-12-16 | 中山大学附属第七医院(深圳) | 一种前列腺癌骨转移诊断、治疗和/或预后的标志物及其应用 |
| CN119007946B (zh) * | 2024-08-02 | 2025-02-07 | 连云港市第二人民医院(连云港市临床肿瘤研究所) | 一种用于肿瘤患者的全病程智能化医疗管理系统 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| JP2000508895A (ja) | 1996-04-05 | 2000-07-18 | ザ ソールク インスチチュート フォア バイオロジカル スタディズ | 哺乳動物系における外来遺伝子の発現を調節するためのホルモン媒介方法と、それに関連した産物 |
| CA2274987C (en) | 1996-12-23 | 2012-01-24 | Immunex Corporation | Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| US6355623B2 (en) | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| EE04911B1 (et) | 1999-03-15 | 2007-10-15 | Axys Pharmaceuticals, Inc. | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| US6525036B2 (en) | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
| ATE348617T1 (de) | 2000-02-16 | 2007-01-15 | Astellas Pharma Inc | Heilmittel gegen durch endothelin verursachte erkrankungen |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| DK2087908T3 (en) | 2001-06-26 | 2018-07-23 | Amgen Inc | ANTIBODIES AGAINST OPGL |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 c-maf의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| JP4579581B2 (ja) * | 2003-12-08 | 2010-11-10 | 株式会社グリーンペプタイド | 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド |
| US20090048117A1 (en) | 2003-12-18 | 2009-02-19 | President And Fellows Of Harvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1706137A2 (en) | 2004-01-21 | 2006-10-04 | Chiron Corporation | M-csf muteins and uses thereof |
| CA2567942A1 (en) | 2004-05-26 | 2005-12-08 | Green Peptide Co., Ltd. | Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP3211086B1 (en) | 2005-09-20 | 2021-06-09 | Menarini Silicon Biosystems S.p.A. | Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| JP5142288B2 (ja) * | 2006-04-05 | 2013-02-13 | 公立大学法人横浜市立大学 | 前立腺癌の予後判定方法及びそのための診断薬 |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| US8623361B2 (en) | 2007-05-24 | 2014-01-07 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| US20110123617A1 (en) | 2007-10-18 | 2011-05-26 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| EP2296654A4 (en) | 2008-06-06 | 2012-04-18 | Univ Health Network | 8-HYDROXYCHINOLINE DERIVATIVES FOR THE TREATMENT OF CRUISING HEMATOLOGICAL DISEASES |
| EP2400851A4 (en) * | 2009-02-25 | 2012-09-05 | Merrion Res Iii Ltd | COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES |
| WO2012045905A2 (es) | 2010-10-06 | 2012-04-12 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
| ES2379918B1 (es) * | 2010-10-06 | 2013-05-10 | Fundació Privada Institut De Recerca Biomèdica | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama. |
| US20140162887A1 (en) | 2011-02-04 | 2014-06-12 | Bioarray Therapeutics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| KR102226219B1 (ko) | 2012-06-06 | 2021-03-10 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 폐암 전이의 진단, 예후 및 치료 방법 |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| JP6074049B2 (ja) * | 2012-10-12 | 2017-02-01 | インバイオモーション エセ.エレ. | c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法 |
| AU2014229505B2 (en) | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20140314792A1 (en) | 2013-03-15 | 2014-10-23 | Institució Catalana De Recerca I Estudis Avançats | Method for the diagnosis, prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| HUE058328T2 (hu) | 2014-06-17 | 2022-07-28 | Asherman Therapy S L | Õssejtterápia endometriális patológiás állapotokban |
| BR112017012515A2 (en) | 2014-12-11 | 2018-01-02 | Inbiomotion S.L. | binding members for human c-maf |
| PL3458610T3 (pl) | 2016-05-25 | 2021-11-22 | Inbiomotion S.L. | Leczenie raka piersi w oparciu o status c-MAF |
| BR112020010192A2 (pt) | 2017-11-22 | 2020-10-13 | Inbiomotion S.L. | tratamento terapêutico de câncer de mama com base no status de c-maf |
-
2013
- 2013-10-09 JP JP2015536237A patent/JP6074049B2/ja active Active
- 2013-10-09 CA CA2888122A patent/CA2888122A1/en not_active Abandoned
- 2013-10-09 HK HK16101721.6A patent/HK1213946A1/zh unknown
- 2013-10-09 US US14/050,262 patent/US20140105918A1/en not_active Abandoned
- 2013-10-09 EP EP13821939.9A patent/EP2906718B1/en active Active
- 2013-10-09 US US14/435,128 patent/US10114022B2/en active Active
- 2013-10-09 WO PCT/IB2013/002866 patent/WO2014057357A2/en not_active Ceased
- 2013-10-09 EP EP19174485.3A patent/EP3553186B1/en active Active
- 2013-10-09 ES ES19174485T patent/ES2906586T3/es active Active
- 2013-10-09 KR KR1020157012297A patent/KR101872965B1/ko active Active
- 2013-10-09 DK DK13821939.9T patent/DK2906718T3/da active
- 2013-10-09 BR BR112015008255-6A patent/BR112015008255B1/pt active IP Right Grant
- 2013-10-09 ES ES13821939T patent/ES2744244T3/es active Active
- 2013-10-09 CN CN201380060218.XA patent/CN104995313A/zh active Pending
- 2013-10-09 MX MX2015004610A patent/MX365421B/es active IP Right Grant
-
2016
- 2016-03-11 JP JP2016048499A patent/JP6446381B2/ja active Active
- 2016-08-10 AU AU2016213773A patent/AU2016213773B2/en active Active
-
2018
- 2018-02-02 JP JP2018017340A patent/JP6636067B2/ja active Active
- 2018-09-18 US US16/134,449 patent/US11041861B2/en active Active
-
2021
- 2021-06-04 US US17/339,024 patent/US11892453B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2906718T3 (da) | Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf | |
| DK2895621T3 (da) | Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande | |
| BR112015000654A2 (pt) | método de formação de imagem, aparelho de formação de imagem, e matéria gravada | |
| DK2885010T3 (da) | Fremgangsmåder til behandling med tauopati | |
| PL2640375T3 (pl) | Sposób leczenia nefropatii pokontrastowej | |
| DK2897620T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3622883T3 (da) | Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger | |
| DK3230736T3 (da) | Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter | |
| PT2683384E (pt) | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| BR112013013584A2 (pt) | endoscópio, e, método | |
| EP2812022A4 (en) | CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS | |
| DK2859017T3 (da) | Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf | |
| DK2838900T3 (da) | Forbindelser og fremgangsmåder til antiviral behandling | |
| DK2663229T3 (da) | Bi-hemisfærisk hjernebølgesystem og fremgangsmåde til at udføre bi-hemisfærisk hjernebølgemålinger | |
| DK2815769T3 (da) | Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet | |
| PT3412687T (pt) | Métodos de tratamento de dlbcl | |
| DK3444613T3 (da) | Fremgangsmåder til diagnosticering og behandling af autisme | |
| BR112014016108A2 (pt) | método de tratamento de perda óssea alvelar | |
| IL240560A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| DK2650049T3 (da) | Hydrogenbehandlingskatalysator og fremgangsmåde til fremstilling af denne | |
| BR112013011659A2 (pt) | métodos de tratamento do câncer | |
| BR112013022820A2 (pt) | método de tratamento | |
| PL2902787T3 (pl) | Sposób oceny reakcji krzepnięcia krwi | |
| DK2896694T3 (da) | Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3214226T3 (da) | Fremgangsmåde og indretning til støjdæmpning |